Zimmer Biomet (NYSE:ZBH) Posts Q4 Sales In Line With Estimates
Medical device company Zimmer Biomet (NYSE:ZBH) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.3% year on year to $2.02 billion. Its non-GAAP profit of $2.31 per share was 0.8% above analysts’ consensus estimates.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 6, 2025 Zimmer Biomet Holdings, Inc. beats earnings expectations. Reported EPS is $2.31, expectations were $2.3. Operator: Good morning, ladies and gentlemen,
Zimmer Biomet Holdings, Inc. (ZBH) Q4 2024 Earnings Call Transcript
Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, February 06,
Zimmer Biomet Holdings Inc. stock underperforms Friday when compared to competitors
Shares of Zimmer Biomet Holdings Inc. ZBH shed 1.71% to $100.93 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.95% to 6,025.
Truist Financial Sticks to Its Hold Rating for Zimmer Biomet Holdings (ZBH)
In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Zimmer Biomet Holdings (ZBH – Research Report).
Earnings call transcript: Zimmer Biomet Q4 2024 sees strong sales growth
Inc. reported robust financial results for the fourth quarter of 2024, surpassing analysts' expectations with an earnings per share (EPS) of $2.31, slightly above the forecast of $2.30. The company's revenue reached $2.
Zimmer (ZBH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Zimmer Biomet (ZBH) reported $2.02 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 4.3%. EPS of $2.31 for the same period compares to $2.20 a year ago.
Zimmer Biomet Holdings Inc. Q4 Profit Decreases, But Beats Estimates
Zimmer Biomet Holdings Inc. (ZBH) announced a profit for fourth quarter that decreased from the same period last year but beat the
Zimmer Biomet price target lowered to $113 from $118 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet (ZBH) to $113 from $118 and keeps a Hold rating on the shares.
ZBH's Q4 Earnings Beat, Margins Contract, Stock Down in Premarket
Zimmer Biomet benefits from its diversified portfolio outside of core orthopedics and the company's strategic investments in ...
Why Is Zimmer Biomet Stock Trading Lower On Thursday?
Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the ...
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH) and Phibro Animal Health (PAHC)
Analysts are pulling back from the Healthcare sector as 2 experts expressed today bearish sentiments on Zimmer Biomet Holdings (ZBH – Research ...
Zimmer Biomet: Adding To The Growth Profile
Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 ...